公开(公告)号：WO2016013829A1

公开(公告)日：2016-01-28

申请号：PCT/KR2015/007513

申请日：2015-07-20

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： AHN, Byoung Ki ,  KO, Ki Seong ,  PARK, So Hyun ,  KI, Min Hyo ,  LIM, Jong Lae

IPC: A61K9/08 ,  A61K31/473 ,  A61K31/573 ,  A61K31/216

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/135 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/5415 ,  A61K31/542 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/28 ,  A61K2300/00

Abstract: Disclosed is a composition comprising a 5α-reductase inhibitor. Forming a liquid crystal upon exposure to an aqueous fluid, the composition can release the 5α-reductase inhibitor at a constant rate over a long period of time. In addition, the composition can significantly alleviate irritations attributed to the topical administration of the 5α-reductase inhibitor, and thus the composition has improved safety.

Abstract translation: 公开了包含5α-还原酶抑制剂的组合物。 在暴露于水性液体时形成液晶，该组合物可以长时间以恒定速率释放5α-还原酶抑制剂。 此外，该组合物可以显着减轻归因于局部施用5α-还原酶抑制剂的刺激，因此组合物具有改善的安全性。

公开(公告)号：WO2020022659A1

公开(公告)日：2020-01-30

申请号：PCT/KR2019/007806

申请日：2019-06-27

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： AHN, Byoung Ki ,  PARK, So Hyun

IPC: A61K9/00 ,  A61K47/44 ,  A61K47/06 ,  A61K31/568 ,  A61P5/24

Abstract: The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.